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Non-alcoholic  fatty  liver  disease  is an  emerging  liver  disease  in  Western  countries  and  the most  frequent
cause  of  incidental  elevation  of serum  liver  enzymes.
Dyslipidaemia  is frequently  observed  in  patients  with  non-alcoholic  fatty  liver  disease,  and  treatment
of  dyslipidaemia  plays  a critical  role  in the  overall  management  of these  patients.  Moreover,  coronary
artery  disease  remains  the most  common  cause  of  death.  Statins  are  effective  lipid-lowering  agents,
associated  with  a lowering  the  risk  of  cardiovascular  events  in several  interventional  randomized  clinical
trials.
However,  statins  are  often  underused  in  patients  with  non-alcoholic  fatty  liver  disease  and  many  physi-
cians  are  concerned  about  the  prescription  of statins  to patients  with  unexplained  persistent  elevation
of  liver  enzymes  or  active  liver  disease.
Based on  currently  available  data,  statin  therapy,  at low-to-moderate  doses,  seems  to  be  safe  and
has  low  liver  toxicity.  Treatment  of dyslipidaemia  in  patients  with  non-alcoholic  fatty  liver  disease  is
recommended  and  may  also improve  liver function  tests.  In  these  patients,  the  risks  of  not  taking  statins
could  outweigh  the  risks  of taking  the  drug.  Conversely,  the  usefulness  of statins  for  the treatment  of
non-alcoholic  fatty  liver  disease/non-alcoholic  steatohepatitis  is  still  a  matter  of  debate  and randomized
clinical  trials  of adequate  size  and duration  are  required.
© 2014  Editrice  Gastroenterologica  Italiana  S.r.l.  Published  by Elsevier  Ltd.  
ND lice. Introduction
Non-alcoholic fatty liver disease (NAFLD) is the most common
nd emerging liver disease in Western countries [1]. Fatty liver
ncludes a wide spectrum of histological alterations ranging from
imple steatosis to non-alcoholic steatohepatitis (NASH), charac-
erized by inﬂammation and ﬁbrosis [2]. Therefore, NAFLD has
een traditionally interpreted as a condition which may  progress
o liver-related complications such as cirrhosis, liver cancer, and
iver mortality [3].
NAFLD  is currently the most common cause of incidental abnor-
Open access under CC BY-NC-al liver tests and elevated serum liver enzyme activities in the
eveloped world. NAFLD is regarded as the liver manifestation
f the metabolic syndrome, as it is strongly associated with
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ttp://dx.doi.org/10.1016/j.dld.2014.07.170
590-8658/© 2014 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. Opobesity, insulin resistance, hypertension, and dyslipidaemia [4],
conditions associated with high cardiovascular risk. Patients with
NAFLD have shown an increased risk for cardiovascular diseases,
and coronary artery disease is the most common cause of death
[5–7].
Statins are among the most-prescribed class of medications
and increasing numbers of patients have received statins in recent
decades in all developed countries. Over the last few years it has
become possible to obtain simvastatin 10 mg over-the-counter in
the United Kingdom and a potential increase in self-medication
is predicted in other countries as well. Recently, the 2013 guide-
lines by the American College of Cardiology (ACC) and the American
Heart Association (AHA) for the treatment of cholesterol expanded
the indications for statin therapy for the prevention of cardiovas-
cular disease [8]. As a consequence, it has been estimated that this
would increase the number of adults who  would be eligible for
nse.statin therapy by 12.8 million, with the increase seen mostly among
older adults without cardiovascular disease [8].
Large scale, well-conducted, placebo-controlled, randomized
clinical trials have established conclusive evidence that the
  en access under CC BY-NC-ND license.
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Table  1
Statins and non-alcoholic fatty liver disease: highlights and open issues.
• Non-alcoholic fatty liver disease is the most common cause of incidental
abnormal elevation of serum liver enzyme activities
•  Non-alcoholic fatty liver disease is associated with dyslipidaemia and
high risk for cardiovascular events
• Statins reduce the risk of major coronary and vascular events
•  Statins are hepatically cleared and can cause elevations in liver
biochemistries
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M•There is a concern that patients with underlying liver disease may  be at
increased risk for hepatotoxicity
ong-term use of statins results in important reductions in the risk
f experiencing major coronary and vascular events in patients
ith a wide range of lipid levels, both in primary and secondary
revention [9,10].
In  primary prevention [10], statin treatment, compared with
lacebo, was associated with lower rates of all-cause mortality (rel-
tive risk [RR], 0.86), combined fatal and nonfatal cardiovascular
isease (RR, 0.75), coronary heart disease events (RR, 0.73), and
atal and non-fatal stroke (RR, 0.78). Statins were also associated
ith reduced coronary revascularization (percutaneous coronary
ntervention and coronary bypass surgery) rates as compared to
ontrols (RR, 0.62) [10].
This effect seems also to be dose-related as reported in a meta-
nalysis by Patti et al. [9] in which high-dose statin treatment
igniﬁcantly reduced periprocedural and 1-month cardiovascular
vents in patients undergoing percutaneous coronary interven-
ion compared to no treatment/low-dose statin treatment (44% risk
eduction).
Nevertheless, despite his proven efﬁcacy, statin administration
s sometimes limited by the concern about related side-effects,
ostly due to muscle and liver injury.
Statins can cause elevations in liver biochemistries and there
s a concern that patients with underlying liver disease may  be
t increased risk for hepatotoxicity (Table 1) [11]. All statins are
leared by the liver and their clearance depends on hydrophobicity
Fig. 1). The more hydrophilic compounds, as pravastatin, exhibit
ore pronounced active renal excretion, while the lipophilic com-
ounds are mainly excreted by the liver (Table 2).
It  has been also suggested that long term statin treatment may
orsen hepatic histology in patients with NAFLD. Many physi-
ians are concerned about the prescription of statins to patients
ith unexplained persistent elevation of liver enzymes or active
iver disease, although the concern for monitoring liver func-
ion in patients taking statins is not shared by all. In fact, in a
ecent survey including 937 primary care physicians, only 50%
ould prescribe statins if the baseline liver alanine aminotrans-erase (ALT) values were 1.5 times the upper limit of normal (ULN)
12].
However, the majority of people who take statins tolerate them
ell and very few experience adverse effects. Occasionally, statin
able 2
ain  pharmacokinetic characteristics of statins.
Atorvastatin Fluvastatin Lovastatin 
Optimal time of dosing Any time of day Bed-time With meals morning
Absorption,  % 30 98 31 
tmax, h 2–4 0.5–1.5 2–4 
t1/2 11–30 0.5–2.3 2.5–3 
Bioavaibility,  % 12 10–35 <5 
Solubility  Lipophilic Lipophilic Lipophilic 
Protein  binding, % >98 >98 96–98.5 
Primary  metabolic pathway CYP3A4 CYP2C9 CYP3A4 
Hepatic  excretion, % >70 >68 >70 
Renal  excretion, % 2 6 30 
odiﬁed from Gazzerro et al. [11].er Disease 47 (2015) 4–11 5
use  could cause a mild rise in serum liver enzymes, which may
rarely become severe and require treatment discontinuation. The
exact mechanism by which statins cause ALT elevations is uncertain
and liver damage is extremely rare. In fact, at currently recom-
mended doses, an elevation of liver enzymes >3 times ULN, occurs
in <1% of treated patients [13,14]. Moreover, it has also been
highlighted that monitoring for hepatotoxicity is ineffective in pre-
dicting serious liver toxicity.
In  this article we will review the available data from the inter-
national literature to summarize current evidence on the safety of
the use of statins in patients with NAFLD.
2. Long-term statin treatment and liver toxicity
2.1. Liver toxicity of statins
Relevant  statin-related liver toxicity is a rare but important
adverse event occurring during statin treatment [15]. In fact, while
asymptomatic elevations in serum ALT are relatively common in
patients treated with statins [15], severe hepatic toxicity has been
rarely described.
Data  from the literature estimate an incidence of acute liver
failure in patients exposed to statins similar to that of the general
population (1:130,000 vs. 1:114,000) (Table 3) [16]. In a cohort of
270 patients undergoing liver transplantation for acute liver fail-
ure, only 3 of the liver recipients had acute liver failure attributed
to a statin (2 to cerivastatin and 1 to simvastatin) over the 12-year
study period [17].
During  statin treatment, an asymptomatic elevation in ALT
should not be considered a sign of ongoing liver disease or injury.
The term of “transaminitis” has been proposed to describe the situ-
ation of liver enzyme leakage without hepatotoxic consequences
[18]. Thus, “transaminitis” may  explain many of the serum ALT
elevations seen in patients treated with statins. There is general
agreement that ALT is more useful than aspartate aminotransferase
(AST) to reveal possible hepatotoxicity, as AST levels may increase
either in muscle and liver injury. Moreover, ALT elevations should
be conﬁrmed in subsequent determinations, as a single ALT eleva-
tion is more suggestive for “transaminitis” than for liver damage. A
possible effect of serum lipid lowering on the structure of cellular
membranes has been hypothesized, allowing for more leakage of
cellular enzymes [18].
Nevertheless,  previous case reports reported that statin use may
induce an autoimmune hepatitis [19–22]. In particular, Alla et al.
[19] described three cases of autoimmune hepatitis after treatment
with ﬂuvastatin in two cases and atorvastatin in the third. Two
similar cases were previously described by Pelli et al. [21] in a 65-
year-old woman  with primary hypercholesterolaemia treated with
atorvastatin, and by Wolters et al. after rosuvastatin administration
[22].
Pravastatin Rosuvastatin Simvastatin
 and evening Bed-time Any time of day Evening
37 50 65–85
0.9–16 3–4 1.3–2.4
0.8–3 20 1.9–3
18 20 <5
Hydrophilic Hydrophilic Lipophilic
43–54 88 >95
Glucuronidation – CYP3A4 CYP2C9–CYP2C19 CYP3A4
46–66 90 78–97
60 10 13
6 D. Pastori et al. / Digestive and Liver Disease 47 (2015) 4–11
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Atorvastatin use was also associated with hepatocellular and
holestatic injury [23–26].
Lovastatin  administration, especially for higher dosage (80 mg
er day), is associated with mild elevations in hepatic enzymes (ALT
3 times the upper limit of normal) in up to 5% of patients. A risk
o develop centrilobular necrosis, cholestasis and fulminant liver
ailure (2/1,000,000 patients) has also been described [23].
For  other statins, such as simvastatin, liver toxicity seems to be
ttributable to drug-drug interactions rather than to simvastatin
tself [23].
.2.  Safety of statin treatment in clinical trials
Overwhelming data now exist that statins are safe in the primary
nd secondary prevention of coronary and vascular events in a wide
ariety of patients.
The  Prospective Pravastatin Pooling (PPP) project [27] combined
he experience from 3 major long-term, large, placebo-controlled
rials of a single dose of pravastatin – the West of Scotland Coronary
revention Study (WOSCOPS) [28], the Cholesterol And Recurrent
vents (CARE) study [29], and the Long-term Intervention with
ravastatin in Ischemic Disease (LIPID) study [30] – to evaluate
otential safety issues. This prospective analysis indicated that
uring prolonged exposure, 40 mg  of pravastatin was well toler-
ted, with no excess of non-cardiovascular serious adverse events,
ncluding liver function abnormalities [31].
A further meta-analysis of randomized, placebo-controlled tri-
ls of statins used for the treatment of hyperlipidaemia or for
rimary or secondary prevention of cardiovascular disease was  per-
ormed on a total of 49,275 patients from 13 trials [32]. The results
upported previous observations that pravastatin, lovastatin, and
imvastatin, at low-to-moderate doses, are not associated with a
igniﬁcant risk of liver function test (LFT) abnormalities and that LFT
onitoring, other than prior to starting therapy, is not warranted
n patients taking a low-to-moderate dose (40 mg/day) [32].ATP: organic anion transporting polypeptides.
The  relationship between statin use, hepatic triglyceride content
(HTGC), and serum ALT levels was also examined in 2,264 Dallas
Heart Study participants who were using no lipid lowering agent
(n = 2124) or using only a statin for lipid management (n = 140) [33].
Statin use was  not associated with a higher frequency of serum ALT
abnormalities, even among those with hepatic steatosis [33].
Recently,  a more aggressive statin therapy was  suggest based
on the results of randomized controlled trials (RCTs) showing a
dramatically decrease of cardiovascular events in secondary pre-
vention (TNT [34], A to Z [35], Prove-IT [36]). In the last year, this
approach was extended by new ACC guidelines also to patients
at high CV risk in primary prevention, such as those with type 2
diabetes (ATP-IV) [8].
Two  meta-analyses addressed the issue of the impact of using
higher vs. lower intensity statin therapy on liver toxicity [37,38].
In the ﬁrst, performed in 23 statin treatment arms with 309,506
person-years of follow-up, raise of liver enzymes increased sig-
niﬁcantly with higher statin dose while there was no signiﬁcant
relationship between LDL-C reduction and hepatotoxicity [37]. The
Authors concluded that the risk of statin associated liver enzyme
elevation is not related to the magnitude of LDL lowering but is
more likely determined by drug- and dose-speciﬁc effects [37].
Similar results were obtained in a second meta-analysis of RTCs
comparing higher vs. lower intensity therapy [38]. However, when
hydrophilic (pravastatin and atorvastatin) and lipophilic (sim-
vastatin and lovastatin) statins were evaluated separately, high
intensity hydrophilic statin therapy increased the risk for transam-
inases elevation, but higher intensity lipophilic therapy did not
[38].
Based on the above data, we  may  conclude that treatment with
low-moderate intensity statins is safe. By contrast, high-intensity
statin treatment may  induce liver toxicity, particularly hydrophilic
statin use.
ESC/EAS guidelines for the management of dyslipidaemia [39]
suggest what to do if liver enzymes became raised in a person taking
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tatins. If ALT < 3xULN, therapy may  be continued and liver enzymes
hecked annually; if values rise ≥ 3xULN, statin treatment should be
iscontinued or reduced in dose and liver enzymes checked within
–6 weeks [39].
By  contrast, a Liver Expert Panel providing advice to the US
ational Lipid Association’s (NLA) Safety Task Force [13] discour-
ged routine liver biochemistry, since severe liver injury with
tatins is rare and unpredictable in individual patients, and mon-
toring individuals with asymptomatic liver enzymes elevation
ould lead to inappropriate therapy discontinuation [13]. This
ecommendation is based on the 2012 safety label changes to
holesterol-lowering statin drugs made by FDA that removed the
eed for routine periodic monitoring of liver enzymes in patients
aking statins [40].
.  Safety and efﬁcacy of long-term statin treatment in
atients  with abnormal liver tests
One common challenge in everyday clinical practice is the pres-
nce of baseline elevations of serum liver enzymes, not infrequently
een in patients at risk of or with established CHD. This abnormality
s frequently secondary to associated comorbid conditions, such as
besity, dyslipidaemia, pre-diabetes, and diabetes mellitus, which
hare features of NAFLD.
The  issue of a possible liver-related adverse effects of statin
reatment in patients with coronary heart disease and liver enzyme
levation was addressed in a post hoc analysis of the Greek Atorvas-
atin and Coronary Heart Disease Evaluation (GREACE) Study [41].
he frequency of liver-related adverse effects was low (1.1%) and
id not differ from rates reported in patients not treated with statins
0.4%; p = 0.2). Additionally, 227 patients with abnormal rises in
ST or ALT concentrations of up to three times the upper limit of
ormal at entry in the trial, who were given a statin had a substan-
ial improvement in liver tests during 3-year follow-up, whereas
10 not treated had a further increase of transaminases. Finally,
he statin-related relative risk reduction was greater in patients
ith abnormal liver tests than in those with normal liver tests. The
uthors conclude that statin treatment is safe and can improve liver
ests and reduce cardiovascular morbidity in patients with mild-to-
oderately abnormal liver tests that are potentially attributable to
on-alcoholic fatty liver disease.
Baseline liver enzymes tests are recommended before initiating
tatin therapy, even though the quality of evidence and grade of
trength are low. In case of elevated liver enzymes at baseline, it
s recommended to repeat liver blood testing in a timely manner
o conﬁrm elevation [13]. Moreover, NLA Safety Task Force estab-
ished the safety of statin in chronic liver disease, NAFLD, NASH and
ompensated cirrhosis. Decompensated cirrhosis and acute liver
ailure are contraindications for statin therapy [13].
.  Statins for the treatment of dyslipidaemia in patients
ith  non-alcoholic fatty liver disease
Hyperlipidaemia is frequently associated with NAFLD. Most
atients with moderately elevated ALT levels have ‘atherogenic
yslipidaemia’, which is characterized by increased serum trigly-
erides, low HDL cholesterol and the presence of small, dense LDL
articles, a common ﬁnding also in insulin resistance and metabolic
yndrome. “Atherogenic dyslipidaemia” is frequently associated
ith other features of metabolic syndrome such as obesity, diabetes
ellitus, and hypertension.
Aggressive  treatment of dyslipidaemia plays a critical role in
he overall management of patients with NAFLD. Statins are the
ainstay of lipid-lowering drug therapy in patients with hyperlip-
daemia. All statins appear to be effective in lowering cholesteroler Disease 47 (2015) 4–11 7
levels  in patients with NAFLD although there is more experience
with atorvastatin which is the only statin to show a reduction in
the incidence of cardiovascular events in these patients [41].
However,  there is concern that patients with NAFLD or NASH
and hyperlipidaemia who  are treated with statins could develop
serum ALT elevation or a further increase of already elevated
enzymes. Therefore, in clinical practice, management of dyslipi-
daemia in patients with NAFLD has been often a matter of concern
and under-treatment with statin therapy because of potential liver
damage. Safety of statin treatment of dyslipidaemia in patients with
NAFLD has been addressed in numerous studies.
High-dose pravastatin (80 mg/day) administered to hyperc-
holesterolemic subjects with chronic liver disease signiﬁcantly
lowered LDL-C, TC, and TGs in comparison with the placebo and was
safe and well tolerated [42]. ALT elevations were numerically more
likely to occur in the placebo group thus supporting the recom-
mendation that hypercholesterolemic patients with compensated
chronic active liver disease should not be denied access to statin
treatment.
In a retrospective study of 71 subjects with NAFLD and dyslip-
idaemia, only 15.4% of patients taking statins experienced a rise
in serum ALT ≥ 40 U/L, and in each case the rise was transient,
returning near baseline or below without discontinuation of statin
treatment [43].
In  some studies the reduction and/or normalization of
serum liver enzymes has been also observed [44–47]. In a
prospective-randomized study, performed in patients with hyper-
cholesterolemia and elevated ALT concentration, pitavastatin and
atorvastatin equally reduced LDL cholesterol and signiﬁcantly
reduced ALT (−8.4% and −8.9% respectively, p < 0.05, analysis of
variance) [44]. In a further prospective study performed in 25 dys-
lipidemic and NAFLD patients with elevated baseline liver enzymes,
36.3% of patients after 6 months and 20% after 12 months of treat-
ment with atorvastatin presented normal ALT levels [45].
Similar  ﬁndings were obtained in a small prospective study on
the treatment of 23 hyperlipidaemic patients with biochemical and
ecographic evidence of NAFLD, where rosuvastatin 10 mg/day for
8 months normalized liver function tests in all patients (mean ALT
from 90.9 to 29.8 U/L, p < 0.001 and mean AST from 91 to 30.5 U/L,
p < 0.001) [46].
Finally, in a study performed in 45 patients with NAFLD,
type 2 diabetes and elevated LDL-C, a signiﬁcant reduction was
observed after 6 months of combined ezetimibe/simvastatin treat-
ment (mean ALT 63.78 vs. 32.57 U/L, p < 0.0001 and mean AST 50.79
vs. 23.68 U/L, p < 0.0001) and simvastatin mono-therapy (mean ALT
66.58 vs. 29.46 U/L, p < 0.0001 and mean AST 59.61 vs. 24.00 U/L,
p < 0.0001). Simvastatin monotherapy reduced ALT to a signiﬁ-
cantly larger extent compared to combined ezetimibe/simvastatin
therapy (p < 0.0112 for ALT, p < 0.0001 for AST) [47].
All  the above data provide evidence that statins can be used
safely to treat hyperlipidaemia in patients with NAFLD. The risk
for serious liver injury from statins is quite rare and patients with
NAFLD and hyperlipidaemia are not at increased risk for statin
hepatotoxicity. Therefore, the presence of NAFLD or NASH should
not deter physicians from using statins in patients with hyperlipi-
daemia.
5. Statins for the treatment of non-alcoholic fatty liver
disease  and non-alcoholic steatohepatitis
Statins have anti-inﬂammatory, anti-oxidant and anti-
thrombotic effects that are independent of their lipid-lowering
activity [48,49]. Therefore, they have been proposed for the
treatment of NAFLD and NASH, since in these conditions both
inﬂammation and oxidative stress play an important pathogenetic
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ole [50]. In particular, in a recent work by our group, we found an
ncreased NOX2-related oxidative stress in patients with NAFLD,
hat was associated with the severity of liver steatosis [50].
No  drug is currently indicated for the treatment of NAFLD/NASH,
ince there is insufﬁcient evidence to support the use of drugs
mproving insulin resistance in these patients [51]. Actually, the
nly therapeutic approach is based on antioxidant treatment with
itamin E for biopsy-proven NASH [52]. So far, very little data about
he effects of statins in NAFLD exists.
In a recent study of Wang et al. [53], simvastatin treatment
mproved the prognosis of NASH-related ﬁbrosis in rat models of
teatosis, by increasing the expression of endothelial nitric oxide
ynthase (eNOS), decreasing the expression of inducible nitric oxide
ynthase (iNOS), and inhibiting the activation of hepatic stellate
ells (HSC) [53].
In  a case report recently described by Riche et al. [54], short-
erm elevations in aminotransferases induced discontinuation of
osuvastatin in an obese dyslipidemic patient with severe NAFLD.
fter 9 months of combined treatment with rosuvastatin 20 mg
aily and pioglitazone 15 mg  daily, the patient’s ALT and AST serum
oncentrations normalized and an improvement in steatosis grad-
ng at ultrasound was found. The authors conclude that this case
epresents a potential solution for initiating or maintaining statin
herapy in patients with NAFLD who are at high cardiovascular risk
54].
In a recent Cochrane meta-analysis on the effect of statins for
AFLD and NASH based on two trials with high risk of bias and a
mall numbers of participants, statins were found to improve serum
minotransferase levels as well as ultrasound ﬁndings [55]. How-
ver, none of the trials reported on possible histological changes,
iver-related morbidity or mortality.An open-label, pilot study evaluated the efﬁcacy of pitavastatin
or the treatment of non-alcoholic steatohepatitis with dyslip-
daemia. After 12 months, follow-up biopsies available for 13
ASH patients showed a slight, non-signiﬁcant reduction of NASH
able 3
eta-analyses on long-term statin treatment and liver toxicity.
Meta-analysis Number of
studies
Total  of
subjects
Age
(years)
Exposure  to study
medication
PPP Project [11] 3 19.768 21–75 >5  years 
de  Denus S [16] 13 49.275 55–75 From 48 weeks to
6.1  years
Alsheikh-Ali  AA [21] 23 treatment
arms
75.317  55–75 From 0.9 to 6.1
years
Dale  KM [22] 9 21.765 48–64 From 1 to 5 years 
DL-C: low-density lipoprotein cholesterol.er Disease 47 (2015) 4–11
activity  score (NAS), while ﬁbrosis stage did not change signiﬁ-
cantly [56]. In one more open-label study by the same Authors in
patients with NASH and hyperlipidaemia [57], follow up biopsies
were performed after 24 months of treatment with atorvastatin
10 mg.  After treatment, liver macrovescicular steatosis and NAS
score were signiﬁcantly improved in both studies, whereas some
patients had increased ﬁbrosis stage. All patients showed a signif-
icant reduction of serum liver enzymes. The Authors suggest that
atorvastatin may  improve disease activity of NASH partly via its
tumour necrosis factor-alpha lowering property [57]. In a study
performed in Sweden, follow up biopsies were obtained 13.8 years
after the ﬁrst liver biopsy in 68 patients with NAFLD. Patients on
statins signiﬁcantly reduced fatty liver inﬁltration over time, as
opposed to those who were not, while liver related biochemical
parameters did not differ signiﬁcantly between the two cohorts
after statin treatment [58].
In the St Francis Heart Study Randomized Clinical Trial, ator-
vastatin 20 mg  combined with vitamins C and E was  effective in
reducing the odds of having hepatic steatosis by 71% (based on
liver to spleen ratio on CT scans) in healthy individuals with NAFLD
at baseline after 4 years of active therapy [59]. Improvement of
liver steatosis was obtained both in NAFLD patients with dyslip-
idaemia and in those without, raising the possibility that, on the
basis of the PIVENS Study [52], vitamin E alone may  have had this
effect.
The effect of multifactorial treatment including lifestyle and
drug treatment for risk factors in subjects with biochemical and
ultrasonographic evidence of NAFLD was assessed in a random-
ized study performed in Greece. After 54 weeks of treatment, 67%
in the atorvastatin, 42% in the fenoﬁbrate and 70% in the combi-
nation treatment groups no longer had any surrogate evidence of
NAFLD, as established by normalization of serum ALT plus normal
liver echopattern [60].
Conversely, negative ﬁndings were obtained in a RCT where
patients with NASH were randomized to simvastatin 40 mg daily or
Treatment  type and
dosage  (mg/day)
Liver function tests
abnormalities
Conclusions
Pravastatin 40 Pravastatin: 0.9%
Placebo:  1.0%
Pravastatin was well
tolerated,  with no
excess  of liver function
abnormalities
Pravastatin 40
Lovastatin  30–45
Simvastatin 27–30
Fluvastatin  40–80
Statins 1.14%
Placebo 1.05%
Only ﬂuvastatin was
associated  with a
signiﬁcant  increase in
the  odds of having liver
function  tests
abnormalities (1.13%
vs.  0.29%)
Lovastatin  20–80
Simvastatin 20–80
Atorvastatin 10–80
Pravastatin  40
Fluvastatin 80
High-dose: 271;
Intermediate: 195;
Low-dose:  114
(per  100,000
person-years for each
10%  reduction in
LDL-C)
Drug-  and
dose-speciﬁc effects
are  more important
determinants of liver
toxicity  than
magnitude of LDL-C
lowering
High dose:
Atorvastatin 80
Simvastatin  40–80
Lovastatin  76
Low  dose:
Simvastatin 20–40
Pravastatin  40
Atorvastatin 10
Lovastatin  4
High-dose statin: 1.5%
Low-dose  statin: 0.4%
Higher intensity statin
therapy  signiﬁcantly
increases the incidence
of  transaminase
elevation in higher
intensity  hydrophilic
statins  group
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Table  4
Summary of the recommendations for statin treatment in patients with non-alcoholic fatty liver disease.
Long-term statin treatment and liver toxicity  Treatment with low-moderate intensity statins is safe. By contrast, high intensity statin
treatment may  induce liver toxicity.
 Discourage routine liver biochemistry monitoring in asymptomatic individuals.
 If ALT < 3xULN, continue therapy and re-check liver enzymes annually.
  If values rise ≥ 3xULN, stop statin or reduce dose and re-check within 4–6 weeks.
Safety and efﬁcacy of long-term statin treatment in
patients  with abnormal liver tests
  Hepatologists are often consulted to advise referring physicians about the safety of prescribing
statins  in patients with elevated serum transaminases.
 This abnormality is frequently secondary to associated comorbid conditions.
 Statin treatment is safe and can improve liver tests.
Statins  for the treatment of dyslipidaemia in patients with
non-alcoholic  fatty liver disease
  Atherogenic hyperlipidaemia is frequently associated with NAFLD.
 Treatment of dyslipidaemia plays a critical role in the overall management of NAFLD.
 The risk for serious liver injury from statins is quite rare and patients with NAFLD and
hyperlipidaemia are not at increased risk for statin hepatotoxicity.
  Previous recommendations advising against the use of statins in patients with dyslipidaemia
and NAFLD are not evidence-based and should be reviewed.
Statins  for the treatment of non-alcoholic fatty liver
disease  and non-alcoholic steatohepatitis
  Preliminary studies have shown that statins may possibly improve hepatic histology in patients
with  underlying NAFLD.
  No convincing histological data are available.
 At present, treatment with statins to cure liver disease in patients with NAFLD is not
ed.
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  New RCTs
treatment o
lacebo [61]. In fact, in 10 subjects who underwent 1-year repeat
iver biopsy, there was no statistically signiﬁcant improvement in
erum ALT, hepatic steatosis, necroinﬂammatory activity or stage
f ﬁbrosis in the simvastatin group. In this pilot study, monother-
py with simvastatin did not seem to be an effective treatment for
ASH, although the small number of subjects under study and the
ow severity of NASH at entry could have been a major limitation
n the interpretation of these negative results [61].
Very recently, data from the population-based Rotterdam Study,
ncluding 2578 subjects who underwent liver ultrasonography,
eported a lower prevalence of liver steatosis in patients treated
ith statins for more than 2 years [62].
. Future research perspectives
Hepatic  effect and metabolism of statin consists of several
o-transporters and enzymes, which are able to regulate both
fﬁcacy and tolerance to statin treatment. In particular, some
olymorphisms in genes affecting statin pharmacodynamics and
harmacokinetics have been described [63]. Among membrane and
ellular drug transporters, two families of plasma membrane pro-
eins play a major role in the intra and inter-cellular networking
f statins: the ATP-binding cassette (ABC) and solute carriers (SLC)
Fig. 1). In the ABC superfamily, the transport of drugs, including
tatins, is mainly associated to the P-glycoprotein (Pg-P/ABCB1),
reast cancer resistance protein (BCRP/ABCG2), and multidrug
esistance-associated proteins (ABCC1 and ABCC2) [63]. Their main
unction is to regulate the diffusion of these agents to other tissues,
nd to eliminate drugs via bile. The alterations of these systems
ave been described to inﬂuence the metabolism of statins.
In  the particular context of NAFLD, some polymorphisms
esponsible for alterations in the progression of fatty liver dis-
ase and lipid metabolism have been described. For example, an
ncreased expression of cytochrome P450-2E1 has been found in
atients with NAFLD [64,65] and polymorphisms in peroxisome
roliferator-activated receptors (PPAR) alpha and gamma2 have
een suggested to be linked to the risk of NAFLD [66].
As  mentioned above, the family of cytochrome P450 is highly
nvolved in the metabolism of statins, thus it would be of great
nterest to understand if the coexistence, in NAFLD patients, of
ultiple gene variants in the intracellular co-transporters of ABCequate size and duration are required to assess efﬁcacy of statins for the
D.
family  and enzymes of the family of cytochrome P450 or PPAR may
further contribute to inﬂuence statin metabolism and safety.
7.  Conclusions
A summary of the efﬁcacy and safety of statins for the treatment
of non-alcoholic fatty liver disease in different clinical settings is
reported in Table 4.
A  large body of data deriving from the large RCTs performed with
statins clearly suggest that statin therapy, at low to moderate doses,
is safe and has very low liver toxicity. Clinically important liver
toxicity is an extremely rare side effect in primary and in secondary
prevention.
Management of “atherogenic dyslipidaemia” associated with
NAFLD plays a pivotal role in the prevention of cardiovascular
events both in primary and secondary prevention.
As far, statins seem to be effective and safe for the treat-
ment of hypercholesterolemia and/or atherogenic dyslipidaemia
in patients with elevated serum liver enzymes, without inducing a
further elevation of liver enzymes in treated patients [58]. There-
fore, an effective treatment of dyslipidaemia should be achieved
even in the presence of chronic liver disease. In fact, statin treat-
ment will reduce cardiovascular events and mortality in these
patients and the risks of not taking statins will likely outweigh the
risks of taking the drug.
Conversely,  the usefulness of statins for the treatment of
NAFLD/NASH is still a matter of debate. Few data suggest nor-
malization of serum liver enzymes. However, no convincing
histological data are available, and the effect of statin treat-
ment on steatosis, inﬂammation and ﬁbrosis are statistically
non-signiﬁcant. Therefore, at present, treatment with statins to
cure liver disease in patients with NAFLD is not recommended.
Further RCTs of adequate size and duration are required to assess
efﬁcacy of statins for the treatment of NAFLD.
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